Featured Research

from universities, journals, and other organizations

New strategy to personalize cancer therapies suggested

Date:
April 29, 2014
Source:
Centro Nacional de Investigaciones Oncologicas (CNIO)
Summary:
A new strategy to personalized medicine in advanced cancer patients with a poor prognosis has been developed by researchers. By applying their new tool, researchers found that their treatments induced clinical responses in up to 77 percent of patients, either through the stabilization of their condition or through a partial clinical response.

This shows personalized therapies in advanced cancer patients according to tumor genetic analysis and avatar mice.
Credit: Elena Garralda (CNIO)

Tumor cells can accumulate hundreds or even thousands of DNA mutations which induce the growth and spread of cancer. The number and pattern of mutations differs according to the type of tumor, even among those that are classified as part of the same type of tumors. This complexity, which researchers were not aware of just a few years ago, calls for new tools to filter relevant genetic information for the implementation and development of personalized therapies targeted at specific characteristics within each individual tumor.

Researchers led by Manuel Hidalgo, Vice-Director of Translational Research at CNIO, have developed a new strategy to personalized medicine in advanced cancer patients with a poor prognosis. The study has been published in the journal Clinical Cancer Research. Applying this new tool, the treatments induced clinical responses in up to 77% of patients, either through the stabilization of their condition or through a partial clinical response.

During the first phase, the authors analyzed the genetic signature of the tumors -specifically, the hundreds of millions of letters that make up the exome; the part of the genome whose information produces proteins- in 23 patients suffering from advanced cancers, such as pancreatic adenocarcinomas and colon cancer. By using whole exome sequencing and bioinformatics analyses, researchers picked out mutations that could play an important role in the growth and spread of tumors.

The second part of the study involved the use of Avatar mice to study potentially effective treatments according to the patient's genetic signature. As Elena Garralda, predoctoral researcher from Hidalgo's Group, points out, avatar mice are "one of the key aspects of our research."

AVATAR MICE: A TESTING GROUND FOR DRUGS

Avatar mice are used as a testing ground, with each patient having their own equivalent animal, in order to study the effectiveness of drugs under real conditions: if the drug works in the avatar, the likelihood of it also working in the patient is very high.

Therefore, the treatments that worked best in the avatar mice were the ones given to patients. The results showed clinical benefit, either the stabilization of the disease or a partial clinical response, in up to 77% of patients.

"We have demonstrated that it is possible to apply our personalized cancer treatment strategy to the clinic," says Garralda, adding: "as we learn more about the genetic information obtained from cancer exome sequencing, future clinical trials will allow for the inclusion of patients with specific genetic alterations, and therefore a better access to cancer drugs."

FUTURE ASSAYS ON PANCREATIC CANCER

Currently, one the main objectives for the team is to study the efficiency of the procedures in a larger number of patients with advanced pancreatic cancer, thereby comparing them to standard treatments.

Pancreatic cancer often has a poor prognosis, with survival rates of less than 1 year. It is a complex and heterogeneous disease, meaning that the personalized study of the most relevant mutations in tumor growth (driver mutations) could be a promising strategy in the search for new treatments.


Story Source:

The above story is based on materials provided by Centro Nacional de Investigaciones Oncologicas (CNIO). Note: Materials may be edited for content and length.


Journal Reference:

  1. E. Garralda, K. Paz, P. P. Lopez-Casas, S. Jones, A. Katz, L. M. Kann, F. Lopez-Rios, F. Sarno, F. Al-Shahrour, D. Vasquez, E. Bruckheimer, S. V. Angiuoli, A. Calles, L. A. Diaz, V. E. Velculescu, A. Valencia, D. Sidransky, M. Hidalgo. Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research, 2014; 20 (9): 2476 DOI: 10.1158/1078-0432.CCR-13-3047

Cite This Page:

Centro Nacional de Investigaciones Oncologicas (CNIO). "New strategy to personalize cancer therapies suggested." ScienceDaily. ScienceDaily, 29 April 2014. <www.sciencedaily.com/releases/2014/04/140429133823.htm>.
Centro Nacional de Investigaciones Oncologicas (CNIO). (2014, April 29). New strategy to personalize cancer therapies suggested. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2014/04/140429133823.htm
Centro Nacional de Investigaciones Oncologicas (CNIO). "New strategy to personalize cancer therapies suggested." ScienceDaily. www.sciencedaily.com/releases/2014/04/140429133823.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins